Introduction
Diabetic retinopathy (DR) is an important complication of diabetes, which progresses from mild to moderate nonproliferative change in retinal microvascular architecture and arterial blood flow to severe proliferative vascular abnormalities (1, 2) . It is widely recognized as the most frequent cause of visual impairment and legal blindness among adults aged 20-74 years (3) , especially in patients with type 1 diabetes mellitus (T1DM) (4) . According to the Wisconsin Epidemiologic Study of Diabetic Retinopathy, nearly all patients with T1DM agents preventing the degradation of endogenous incretin hormones: glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic peptide (GIP) seem to have an effect beyond glycemic control (14) . There are several studies indicating that DPP4 inhibitors might have a beneficial effect on nonproliferative retinopathy (NPR) development as well as on its progression to proliferative retinopathy (PR) (15) (16) (17) . We aimed to explore the relationship between serum DPP4 activity and DR in patients with T1DM.
Materials and Methods
This cross-sectional study undertaken at the University Clinic for Diabetes, Endocrinology, and Metabolic Diseases Vuk Vrhovac (Zagreb, Croatia) recruited 44 T1DM C-peptidenegative (C-peptide <0.5 ng/mL) patients aged >18 and <65 years coming for their comprehensive annual review. This specification was added since C peptide was shown to play a protective role in retinopathy development and progression (18) . The sample size was in accordance with G power 3.1.7 calculation for correlations (2-tailed t test, total sample size = 44, α = 0.05, 1-β = 0.8, ρ = 0.4). The inclusion criteria were age at onset of diabetes younger than 40 years, positive autoantibodies, and time to definite insulin therapy less than a year. Exclusion criteria were medical history of cardiovascular diseases or electrocardiogram evidence of ischemic heart disease, any systemic disease or infection in the previous month, thyroid hormone therapy, and medications that might affect glucose metabolism and insulin sensitivity such as glucocorticoids or oral contraceptives. The study subjects could be using antihypertensive or lipid-lowering drugs (i.e., statins: atorvastatin and simvastatin). All the patients were treated with conventional intensified insulin therapy with basal insulin (detemir or glargine) and short-acting insulin (aspart) in 3 subcutaneous injections per day.
Anthropometric measurement and standard laboratory procedures were conducted as previously described (19) . Fasting venous blood samples were collected for the determination of biochemistry panel, lipid profile status, glycated hemoglobin A1c (HbA1c), and serum DPP4 activity. After clotting, the sera were separated and kept at −70°C until the determination of enzymatic activity. The DPP4 activity was measured by a colorimetric assay procured from Sigma (St. Louis, Missouri, USA) in a microplate reader (Cary Eclipse Varian, Agilent Technologies, Santa Clara, California, USA) at 460 nm, 37°C, continuous monitoring for 35 minutes. In this assay, DPP4 cleaves H-Gly-Pro-AMC to release a florescent product, 7-amino-4-methyl coumarin (AMC), which can be measured spectrophotometrically. All the DPP4 assays were run in duplicate. Briefly, 50 μL of serum sample was added to 96-well plates, followed by the addition of 10 μL assay buffer. After 10 minutes of preincubation at 37°C, the enzymatic reaction was started with the addition of 40 μL of Master Reaction Mix containing 2 μL substrate and 38 μL of the assay buffer. Liberation of AMC was monitored continuously at excitation 360 nm and emission 460 nm every 5 minutes for up to 35 minutes in a 96-well black flat bottom plate. Fluorometric catalysis rates were determined from the linear portion of the curve of the increase in fluorescence and were calculated as the slope of the regression line determined from the line.
The DPP4 activity was expressed as pmol/min/mL (U/L). One unit of activity was defined as the amount of enzyme that will hydrolyze the DPP4 substrate to yield 1.0 µmol of AMC per minute at 37°C.
Diabetic retinopathy was tested in a specialized clinical ambulance by an ophthalmologist/retinal specialist. Retinopathy was diagnosed by binocular indirect slit-lamp funduscopy and fundus photography after mydriasis with eyedrops containing 0.5% tropicamide and 5% phenylephrine. Color fundus photographs of 2 fields (macular field, disc/nasal field; macular field positioned in such a way that the exact center of the optic disc lay at the nasal end of the horizontal meridian of the field view; disc/nasal field: such that the optic disc was positioned 1 disc diameter in from the temporal edge of the field, on the horizontal meridian) of both eyes were taken with a suitable 45° fundus camera (VISUCAM, Zeiss, Oberkochen, Germany) according to the EURODIAB retinal photography methodology (20) . The EURODIAB classification scheme was used because it uses 2-field 45° fundus photography and standard photographs to grade retinal lesions. In each patient the worse eye was graded for retinopathy using fundus photographs. Patients were classified into 2 groups: absence of DR and DR (both PR + NPR) presence, as NPR may progress to PR and thus patients with DR may belong to the second group at a certain time point.
Data analysis and statistics
Data distribution was assessed by Shapiro-Wilk test. All the continuous variables were log-transformed and reported as mean values and 95% confidence interval of means, whereas categorical variables were reported as numbers and percentages. Because we found normal distribution of the data, differences among 3 study groups were tested by oneway analysis of variance followed by Bonferroni correction for multiple comparisons, differences between 2 study groups were tested by Student t test, and categorical variables were analyzed by the χ 2 test. Binary logistic regression analysis was used to predict the probabilities of the associations of variables that reached significance in the univariate analysis with DR groups including the nonsignificant possible confounding factors (age and sex). Level of statistical significance was chosen to be 0.05. Statistical analysis was performed by Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL) v 17.0 and MedCalc 11.0 for Windows.
Results
The clinical characteristics and the fasting serum DPP4 activity of 44 patients with T1DM included in this cross-sectional study are described in Table I . Briefly, there were 28 (63.6%) male patients, mean age 45.36 years, diabetes duration 23.71 years, HbA1c of 7.4%. Thirty patients (68.2%) were using statins, i.e., atorvastatin, and 22 (50%) antihypertensive agents, which all included verapamil in therapy. Ten (22.73%) patients were smokers. Twelve (27.3%) patients had previous laser photocoagulation due to PR. They were stratified into 2 groups according to retinopathy prevalence. Group 1 comprised 14 (31.85%) with DR absence and group 2 30 (68.15%) with both NPR (n = 21, 47.70%) and PR (n = 9, 20.45%) prevalence. The average total daily insulin dose was not significantly different between groups (0.62 U/kg vs 0.65 U/kg, p = 0.32). Group 1 had significantly shorter diabetes duration (16.43 vs 27.1 years, p = 0.002), lower HbA1c level (6.9% vs 7.9% vs 7.7%, p = 0.019), and lower fasting serum DPP4 activity (25.85 vs 33.39 vs 34.91 U/L, p<0.001) when compared to group 2 (Tab. II). History of previous laser photocoagulation was positive only in group 2 (12 vs 0; p<0.00001). There were no patients with history of laser photocoagulation due to macular edema. The between-group difference in use of statins or antihypertensive therapy did not reach statistical difference (data not shown). In the binary logistic regression model adjusted for age, sex, diabetes duration, HbA1c level, and history of laser photocoagulation, DPP4 activity remained associated with DR (1.637 [1.129-2.373]; p = 0.009) (Tab. III).
Discussion
Because DPP4 inhibitors have been successfully introduced in T2DM treatment, showing beneficial pleiotropic effect beyond glycemic control for this class of drugs (14, 21) , and due to a simultaneously growing body of evidence about increased serum DPP4 activity in patients with T1DM (12, 13) , this cross-sectional study was designed primarily in order to elucidate the possible association of serum DPP4 activity and DR, the most frequent microvascular complication in diabetes (3, 4) . Metabolic and anthropometric variables and fasting serum DPP4 activity were assessed in 2 groups of patients with T1DM according to the DR prevalence. Beyond already well-established factors associated with DR (diabetes duration and HbA1c), we showed that serum DPP4 activity is significantly higher in patients with T1DM with DR and that the association remained significant in the binary regression analysis after appropriate adjustments. To our knowledge, there are no data about DPP4 activity and DR in T1DM. Although the effect of DPP4 inhibition on diabetic vasculature is still being discussed, its clinical application in T2DM glycemia management is reported to provide beneficial effects regarding oxidation, apoptosis, and vasoprotection, suggesting that it might be a useful tool in DR improvement (15) (16) (17) . It is well-established that EPCs are considered a mirror of cardiovascular health (22) and their circulating levels are decreased in diabetic subjects compared to healthy controls (10) . Tissue ischemia is the strongest stimulus for EPC mobilization from bone marrow (11) . Avogaro et al (8) proposed that the majority of cytokines that mediate EPCs mobilization do so via modulation of SDFα or its receptor, CXCR4. Moreover, in order to heal damaged endothelium, EPCs are required to migrate from bloodstream to target tissues, which is again mediated by high local levels of SDFα. All those pathways are attenuated by increased DPP4 activity since it degrades SDFα. That is why pharmacologic inhibition of circulating DPP4 activity might resaturate hyperglycemia-induced endothelial dysfunction, i.e., mediate endothelial repair. In theory, that could explain our finding regarding increased DPP4 activity and DR prevalence, especially when concerning NPR. However, since NPR may progress to PR, the increased DPP4 activity association with DR prevalence might seem paradoxical. It is expected that higher DPP4 activity leads to SDFα cleavage and the decreased neovascularization process that exists in PR. This DPP4-mediated retinopathy angiogenic paradox can be explained by 2 theories. First, there is evidence that peripheral EPCs from human patients with T1DM with PR display higher clonogenic potential and enhanced endothelial differentiation (23, 24) , so we may speculate that those EPCs overcome the process of endothelial reparation and lead to pathologic endothelial proliferation. Second, hyperglycemiainduced retinal ischemia induces pericyte loss, an early event leading to endothelial activation and the release of local proangiogenic factors resulting in endothelial proliferation and PR development (8, 25) . In addition, DPP4 inhibition reduces microvascular tone through direct nitric oxide system, preventing acute retinal ischemia events (26) . Therefore, we can conclude that increased serum DPP4 activity might increase vascular tonus, resulting in pericyte loss and retinal endothelial proliferation. Finally, hyperglycemia expressed as HbA1c is recognized as the most important factor for DR development and progression in T1DM (6) . Increased systemic DPP4 activity degrades incretin hormones GLP-1 and GIP, analogues of which are primarily used in T2DM glucoregulation (27) , but might also benefit glycemic control in patients with T1DM, as recently suggested (28) . The use of GLP-1 analogues provides blood lipid improvements, lowers blood pressure, and improves markers of renal function, particularly albuminuria, which are all associated with DR (6, 7). In addition, more homogenecity with human GLP-1 seems to provide a better effect (14, 24, 29, 30) . The increased serum DPP4 activity might increase the degradation process of endogenous GLP-1, resulting in worsening of the mentioned parameters, which was also observed in our study, although the difference did not reach statistical difference.
This study has several limitations: the sample size was small and we accessed only systemic DPP4 activity; we did not measure EPCs or GLP-1, so no general conclusion about their relationship with DR can be made. However, we can conclude that serum DPP4 activity may be associated with both DR types in T1DM independently of HbA1c and diabetes duration or that it might play an important role in pathophysiology of its development. Further investigation in a larger sample is warranted to elucidate whether there is a strong association between DPP4 activity and DR severity and/or progression and, if so, what is the underlying mechanism.
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